Loading stockRelated stocks: Agricultural Services
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockRelated stocks: Agricultural Services
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as the Company, CTi, we, us, and our ) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. We are a process and product development firm that has developed, patented, and commercialized environmentally friendly technology-based systems that are designed to serve large, growing, global mark…
$0.05
$0.00 (-7.00%)
EOD Sep 1, 2026
The business is unprofitable at the operating level (-486.21% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 85.1% YoY. Margins deteriorated 518.3pp alongside, both lines moving the wrong way.
ROIC dropped from 151.76% to -400.89%, capital efficiency is deteriorating. Operating margin contracted 518.3pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$11K
▼ -85.1% YoY
Net Income (TTM)
-$1M
▼ -125.7% YoY
Op. Margin
-10800.00%
▼ -518.3pp YoY
ROIC
-504.58%
▼ -552.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$709K
▼ -568.6% YoY
Net Debt
$195K
Cash & Equiv.
$45K
5Y CAGR: -34.3%
Continue Research
SourceComputed from the 10-Q filed 20 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 21 May 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.
Cavitation Technologies (CVAT)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cavitation Technologies scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Cavitation Technologies scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -10,800.0% operating margin and a -504.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CVAT's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.